Combination of immunotherapy and targeted therapy boosts colorectal cancer survival, clinical trial finds

0
9

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of cancer death in the U.S., live longer and control their disease better than with the standard treatment drug regorafenib.

This post was originally published on this site

This site uses Akismet to reduce spam. Learn how your comment data is processed.